Investor Pre-Day (PRE BOOK ONLY)

PLEASE NOTE YOU MUST HAVE PRE BOOKED TICKET TO ATTEND THIS EVENT

Exploring the CGT Investment Landscape: Opportunities in Tech and Treatments

11am Welcome Address

Representative, Dark Horse Consulting

11.10am Fireside Chat: Global Cell & Gene Therapy Market Analysis

• 2023 year in review and 2024 outlook.
• Companies: what needs to be different going forward. Platforms vs Products
• CMC and other support issues needed for advanced therapies to thrive.
• Battle of the modalities. When does a cell or gene therapy make sense against a traditional treatment?
• Future outlook for CAR-T.
• Launching BiotechTV. The idea behind it.

Brad Loncar, Chief Executive Officer, Loncar Investments

11.25am Exploring Investment Opportunities within Therapeutics

Chairperson: Asthika Goonewardene, Managing Director, Truist Securities

Eric Shiozaki, Partner, DCVC Bio

Michael E. Meyers, Vice Chairman Head of M&A and Strategic Advisory Services, H.C. Wainwright & Co., LLC

Tiziana Rossetti, Senior Associate, Telethon Fund Strategy, Sofinnova

12.00pm Exploring Investment Opportunities within Tools & Technology

Daniella Kranjac, Founding Partner, Dynamk Capital

Eric Shiozaki, Partner, DCVC Bio

Charles Purtell, Vice President Equity Ventures, Danaher Corp

Philp Vanek, Chief Technology Officer, Gamma Biosciences

Daniel Friedman, Vice President, BroadOak Capital Partners

12.30pm Networking Break & Lunch

A 90 minute, 3 course exclusive networking lunch: Connect with industry peers, discover fresh faces, and forge invaluable relationships to secure your financial growth over the next year.

2pm Preparing For A Successful Investment In CGT

Aaron Vernon, Chief Manufacturing Officer, Quell Therapeutics Limited

Dhvanit Shah, Chief Executive Officer, Garuda Therapeutics

Scott Cross, Senior Principal, Dark Horse Consulting Group

Christian Barkey, Chief Executive Officer, Swissfinity Group

Robert Allen, Managing Partner & EU General Manager, Dark Horse Consulting Group

Bryan Poltilove, Advisor, Broad Oak Capital Partners

2.40pm Closing Address

Representative, Dark Horse Consulting

2.45pm Event End